Similarly, the co-administration of DOX with cisplatin or knockdown of Notch1 in osteosarcoma reduced the cytotoxic effects of DOX via the unanticipated upregulation of Notch1 and related target genes [102]. The gene discussed is NOTCH1; the disease is osteosarcoma.